活检确诊的非酒精性脂肪性肝病患者的癌症风险:一项基于人群的队列研究
该研究基于瑞典1966至2016年所有经肝活检确诊的NAFLD成人(N=8,892),按年龄、性别、日历年、县匹配无NAFLD的普通人群对照(N=39,907)。中位随访13.8年,NAFLD患者总体癌症发病率显著升高(aHR 1.27, 95%CI 1.18-1.36),主要归因于肝细胞癌(HCC)风险大幅增加(aHR 17.08, 95%CI 11.56-25.25),肝外癌症贡献较小。
要点
- 活检确诊NAFLD患者总体癌症风险显著增加(aHR 1.27),主要由HCC驱动(aHR 17.08)。
- HCC发病率随单纯脂肪变、非纤维化NASH、非肝硬化纤维化、肝硬化逐级递增(P趋势<0.01)。
- 糖尿病进一步放大各纤维化阶段的HCC风险。
核心结论
- 与对照相比,活检确诊的NAFLD患者癌症发病率显著增加,主要归因于HCC,肝外癌症贡献较小。
研究设计与样本
- 基于瑞典1966至2016年所有经肝活检确诊的NAFLD成人(N=8,892)的人群队列研究,按年龄、性别、日历年、县与无NAFLD的普通人群对照(N=39,907)个体匹配。
主要发现
- 中位随访13.8年,NAFLD患者发生1,691例癌症,对照发生6,733例。
- NAFLD患者总体癌症发病率显著高于对照(10.9 vs. 13.8每1,000人年;差值=2.9每1,000人年;aHR 1.27, 95%CI 1.18-1.36)。
- HCC风险大幅增加(差值=1.1每1,000人年;aHR 17.08, 95%CI 11.56-25.25)。
- HCC发病率在单纯脂肪变、非纤维化NASH、非肝硬化纤维化、肝硬化中分别为0.8、1.2、2.3、6.2每1,000人年(P趋势<0.01),合并糖尿病时分别为1.2、2.9、7.2、15.7每1,000人年。
- NAFLD与胰腺癌、肾/膀胱癌、黑色素瘤风险轻度增加相关(差值分别为0.2、0.1、0.2每1,000人年),与其他癌症无关。
关键数值与推荐
- NAFLD定义依据前瞻性记录的肝组织病理学,分为单纯脂肪变、非纤维化NASH、非肝硬化纤维化和肝硬化。
- HCC发病率随纤维化分期加重而单调递增(P趋势<0.01),糖尿病进一步放大风险。
临床怎么用
- 对活检确诊NAFLD患者应重视HCC监测,尤其是非肝硬化纤维化和合并糖尿病者。
- 肝外癌症风险增加幅度较小,但胰腺癌、肾/膀胱癌和黑色素瘤仍需关注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Recent studies link NAFLD to an increased incidence of HCC and extrahepatic cancers. However, earlier studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity. APPROACH AND RESULTS: We conducted a population-based cohort study of all adults with histologically defined NAFLD in Sweden from 1966 to 2016 (N = 8,892). NAFLD was defined from prospectively recorded liver histopathology submitted to all 28 Swedish pathology departments and categorized as simple steatosis, nonfibrotic NASH, noncirrhotic fibrosis, and cirrhosis. NAFLD patients were individually matched to ≤5 general population controls without NAFLD by age, sex, calendar year, and county (N = 39,907). Using Cox proportional hazards modeling, we calculated multivariable adjusted HRs (aHRs) and 95% CIs. Over a median of 13.8 years, we documented 1,691 incident cancers among NAFLD patients and 6,733 among controls. Compared with controls, NAFLD patients had significantly increased overall cancer incidence (10.9 vs. 13.8 per 1,000 person-years [PYs]; difference = 2.9 per 1,000 PYs; aHR, 1.27 [95% CI, 1.18-1.36]), driven primarily by HCC (difference = 1.1 per 1,000 PYs; aHR, 17.08 [95% CI, 11.56-25.25]). HCC incidence rates increased monotonically across categories of simple steatosis, nonfibrotic NASH, noncirrhotic fibrosis, and cirrhosis (0.8 per 1,000 PYs, 1.2 per 1,000 PYs, 2.3 per 1,000 PYs, and 6.2 per 1,000 PYs, respectively; Ptrend < 0.01) and were further amplified by diabetes (1.2 per 1,000 PYs, 2.9 per 1,000 PYs, 7.2 per 1,000 PYs, and 15.7 per 1,000 PYs, respectively). In contrast, NAFLD was associated with modestly increased rates of pancreatic cancer, kidney/bladder cancer, and melanoma (differences = 0.2 per 1,000 PYs, 0.1 per 1,000 PYs, and 0.2 per 1,000 PYs, respectively), but no other cancers. CONCLUSIONS: Compared with controls, patients with biopsy-proven NAFLD had significantly increased cancer incidence, attributable primarily to HCC, whereas the contribution of extrahepatic cancers was modest. Although HCC risk was highest with cirrhosis, substantial excess risk was also found with noncirrhotic fibrosis and comorbid diabetes.
引用
- Simon TG, Roelstraete B, Sharma R, et al. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology. 2021. PMID: 33811766. doi:10.1002/hep.31845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。